Orchestra BioMed Holdings, Inc.·4

Feb 13, 5:01 PM ET

Sherman Darren 4

4 · Orchestra BioMed Holdings, Inc. · Filed Feb 13, 2026

Research Summary

AI-generated summary of this filing

Updated

Orchestra BioMed (OBIO) President Darren Sherman Receives Award

What Happened Darren Sherman, President and Chief Operating Officer (and director) of Orchestra BioMed Holdings, was granted 397,000 restricted stock units (RSUs) on February 12, 2026. The award was reported as an acquisition/award (code A) at $0.00 per share (no cash payment). These RSUs represent contingent rights to receive common stock in the future subject to vesting.

Key Details

  • Transaction date: 2026-02-12; Report filed: 2026-02-13 (timely).
  • Grant: 397,000 RSUs; reported price per share: $0.00; immediate cash value reported: $0.
  • Shares owned after transaction: not specified in the filing.
  • Footnote: Each RSU equals a contingent right to one share. Vesting schedule: 25% vests 18 months after the issue date (Feb 12, 2026), then 25% at 24 months, 25% at 30 months, and 25% at 36 months, subject to continuous service.
  • Remarks: Sherman is President and Chief Operating Officer.

Context RSUs are compensation awards that convert into shares only upon vesting; they do not represent immediate transferable stock or a cash outlay by the insider. Such grants are routine forms of executive compensation and do not by themselves indicate an insider buying or selling stock in the open market.

Insider Transaction Report

Form 4
Period: 2026-02-12
Sherman Darren
DirectorSee Remarks
Transactions
  • Award

    Common Stock, par value $0.0001 per share

    [F1]
    2026-02-12+397,0001,237,569 total
Footnotes (1)
  • [F1]Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 25% of the shares will vest 18 months after February 12, 2026 (the "Issue Date"), (ii) 25% of the shares will vest 24 months after the Issue Date, (iii) 25% of the shares will vest 30 months after the Issue Date and (iv) 25% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates.
Signature
/s/ Andrew Taylor, Attorney-in-Fact|2026-02-13

Documents

1 file
  • 4
    tm266316-3_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT